Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
102 hedge funds and large institutions have $120M invested in Jounce Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 35 increasing their positions, 32 reducing their positions, and 23 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 32
10% less funds holding
Funds holding: 113 → 102 (-11)
35% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 23
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
58% less capital invested
Capital invested by funds: $285M → $120M (-$165M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$11M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.64M |
| 3 |
BlackRock
New York
|
+$960K |
| 4 |
Renaissance Technologies
New York
|
+$939K |
| 5 |
Invesco
Atlanta,
Georgia
|
+$873K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.51M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.52M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2.43M |
| 4 |
RI
RTW Investments
New York
|
-$1.57M |
| 5 |
Barclays
London,
United Kingdom
|
-$922K |
JNCE Hedge Fund Activity: Q2 2022 in Review
102 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2022, worth a combined $120M — down 58% from $285M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of JNCE and 15 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 35 added.
The largest buyer was Cowen and Company, adding an estimated $11M. The largest seller was Logos Global Management, exiting entirely with an estimated $9.51M sold.
- 102 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2022, down from 113 in Q1 2022.
- Funds reported $120M of Jounce Therapeutics, Inc. Common Stock stock for Q2 2022, down 58% quarter-over-quarter.
- 15 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2022 and 23 closed out, a net change of -8 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q2 2022 was Cowen and Company, an estimated $11M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2022 was Logos Global Management, an estimated $9.51M sold.
Based on aggregated 13F filings for Q2 2022.